"Purines" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A series of heterocyclic compounds that are variously substituted in nature and are known also as purine bases. They include ADENINE and GUANINE, constituents of nucleic acids, as well as many alkaloids such as CAFFEINE and THEOPHYLLINE. Uric acid is the metabolic end product of purine metabolism.
| Descriptor ID |
D011687
|
| MeSH Number(s) |
D03.633.100.759
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Purines".
Below are MeSH descriptors whose meaning is more specific than "Purines".
This graph shows the total number of publications written about "Purines" by people in this website by year, and whether "Purines" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 1 | 1 |
| 1997 | 1 | 1 | 2 |
| 2000 | 0 | 2 | 2 |
| 2001 | 0 | 1 | 1 |
| 2002 | 0 | 2 | 2 |
| 2003 | 0 | 2 | 2 |
| 2004 | 0 | 3 | 3 |
| 2006 | 1 | 1 | 2 |
| 2007 | 0 | 1 | 1 |
| 2008 | 2 | 0 | 2 |
| 2009 | 0 | 2 | 2 |
| 2010 | 2 | 1 | 3 |
| 2011 | 2 | 2 | 4 |
| 2012 | 3 | 2 | 5 |
| 2013 | 1 | 0 | 1 |
| 2014 | 0 | 2 | 2 |
| 2015 | 0 | 1 | 1 |
| 2016 | 3 | 2 | 5 |
| 2017 | 1 | 1 | 2 |
| 2018 | 1 | 1 | 2 |
| 2020 | 1 | 0 | 1 |
| 2021 | 1 | 0 | 1 |
| 2022 | 0 | 1 | 1 |
| 2023 | 0 | 3 | 3 |
| 2024 | 2 | 1 | 3 |
| 2025 | 0 | 1 | 1 |
| 2026 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Purines" by people in Profiles.
-
Machine Learning-Based Prediction of Distant Recurrence Risk and Ribociclib Treatment Effect in HR+/HER2- Early Breast Cancer Using Real-World and NATALEE Data. Clin Cancer Res. 2026 Jan 16; 32(2):428-437.
-
CDK4/6 inhibition in early and advanced hormone receptor-positive, HER2-negative breast cancer. Expert Rev Anticancer Ther. 2025 Jun; 25(6):675-686.
-
Evaluation of cyclin-dependent kinase 4/6 inhibitor-induced serum creatinine elevations in patients with hormone receptor positive breast cancer. J Oncol Pharm Pract. 2026 Jun; 32(4):641-647.
-
Identification of CDK4/6 Inhibitors as Small Molecule NLRP3 Inflammasome Activators that Facilitate IL-1ß Secretion and T Cell Adjuvanticity. J Med Chem. 2024 09 12; 67(17):14974-14985.
-
Electron transport chain inhibition increases cellular dependence on purine transport and salvage. Cell Metab. 2024 Jul 02; 36(7):1504-1520.e9.
-
Purine-ifying uric acid by gut microbes. Cell Chem Biol. 2023 07 20; 30(7):706-708.
-
Role of adenosine A2A receptors in hot and cold cognition: Effects of single-dose istradefylline in healthy volunteers. Eur Neuropsychopharmacol. 2023 06; 71:55-64.
-
Endoplasmic reticulum stress in the intestinal epithelium initiates purine metabolite synthesis and promotes Th17 cell differentiation in the gut. Immunity. 2023 05 09; 56(5):1115-1131.e9.
-
A Phase Ib/II Study of the CDK4/6 Inhibitor Ribociclib in Combination with Docetaxel plus Prednisone in Metastatic Castration-Resistant Prostate Cancer. Clin Cancer Res. 2022 04 14; 28(8):1531-1539.
-
MTHFD2 is a metabolic checkpoint controlling effector and regulatory T cell fate and function. Immunity. 2022 01 11; 55(1):65-81.e9.